ClinicalTrials.gg
RecruitingNCT03853447Updated Apr 8, 2020

Fibro-inflammatory Progression From Acute to Chronic Pancreatitis

An observational study in Pancreatitis, Acute Pancreatitis and Recurrent Pancreatitis, sponsored by Copenhagen University Hospital, Hvidovre. Recruiting at 3 sites in Denmark. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Primary conditionPancreatitis, ChronicRegistry: PancreatitisReclassifiedWhy we changed it
Registry
Pancreatitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pancreatitis, Chronic
Why
  1. The study's listed conditions name Pancreatitis, Chronic, a narrower term within Pancreatitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Copenhagen University Hospital, Hvidovre · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Pancreatitis, Chronic with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Pancreatitis, Chronic · Denmark.

Started
2019
the only one that year
Observational
6 of 14
2 open now
Registered
9th of 14
by date
Lead sponsor
2 of 14
Copenhagen University Hospital, Hvidovre

Among the 14 studies in Pancreatitis, Chronic with a site in Denmark, this one is the only one that started in 2019, is one of 6 observational ones, and was the 9th registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

2 of the 14 studies in Pancreatitis, Chronic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pancreatitis, Chronic with a site in Denmark, or all of them as a file.
02

Study summary

Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.

Read the detailed description

Chronic pancreatitis (CP) represents the end-stage of a continuous disease process evolving from acute pancreatitis (AP), over recurrent acute pancreatitis (RAP). Due to the irreversible nature of CP, early detection and prevention is key. The study uses state-of-the-art imaging modalities as well as biochemical markers of to evaluate fibrosis progression in patients with pancreatitis.

The included participants have either first time AP, RAP, early CP with preserved pancreatic exocrine and endocrine function or end-stage CP with exocrine insufficiency. Included patients will be followed prospectively for 15 years with advanced MRI and contrast enhanced EUS with elastography, assessment of endocrine and exocrine pancreatic function, biochemical and nutritional assessment, and evaluation of pain processing using quantitative sensory testing. Blood for a biobank will be obtained. The purpose of the biobank is to allow analyses of potential biomarkers for the progression of disease eventually leading to CP.

03

Conditions studied

  • Pancreatitis
  • Acute Pancreatitis
  • Recurrent Pancreatitis
  • Chronic Pancreatitis
  • Inflammation
  • Fibrosis

Browse trials for

04

In context

Pancreatitis, Chronic Reclassified

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

This study's planned enrollment of 150 is below the median of 300 across 117 observational studies indexed under Pancreatitis, Chronic.

Browse Pancreatitis, Chronic studies →

Lead sponsor

Copenhagen University Hospital, Hvidovre is the lead sponsor of 79 studies on the registry; 19 are open to participants now.

Compared within Pancreatitis, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with CP, AC pr RAP who are not:

  1. Pregnant or lactating patients
  2. Contraindications to magnetic resonance imaging (MRI) or endoscopic ultrasound
  3. Known chronic liver disease, chronic renal failure, malignancy, chronic inflammatory bowel syndrome, chronic obstructive lung disease, pulmonary fibrosis.
  4. Treatment with anti-inflammatory drugs of any kind at the time of inclusion.

Inclusion criteria

  • Patients with CP (N=50) of any aetiology except gallstone induced CP: CP will be diagnosed based on MANNHEIM criteria .
  • Cohort 2: Patients with their first attack of AP of any aetiology except gallstone induced AP (N=50). The revised Atlanta criteria for acute pancreatitis will be used as diagnostic criteria.
  • Cohort 3: Patients with RAP (N=50) except gallstone induced RAP. RAP is defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.

Exclusion criteria

Exclusion Criteria:

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Diagnostic imaging

    The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM. Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP. Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.

    Diagnostic Test: Diagnostic imaging

Interventions

  • Diagnostic testDiagnostic imaging

    MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS

    Also known as: MRI and EUS

07

What researchers measure

Primary outcomes

  1. Fibrosis progression on endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI)

    Progression of fibrosis in the pancreas based on either EUS or MRI

    Time frame: 15 years

Secondary outcomes

  1. Lean body mass assessed using bioimpedance

    Body composition focusing on lean body mass will be assessed using bioimpedance

    Time frame: 15 years

08

Study locations

3 of 3 sites recruiting
  • Gastrounit, Copenhagen University Hospital Hvidovre
    Hvidovre, Capital Region Denmark 2650, Denmark
    Recruiting
  • Department of Gastroenterology & Hepatology, Aalborg University Hospital
    Aalborg, 9000, Denmark
    Recruiting
  • Abdominal Centre, Bispebjerg University Hospital
    Copenhagen, 2200, Denmark
    Recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Jan 2040, 250 months after the start.

Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 250 months is above that.

Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 25, 2019
StartActual
Feb 14, 2019
Primary completionEst.
Jan 1, 2040
CompletionEst.
Jan 1, 2041
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03853447
Lead sponsor
Copenhagen University Hospital, Hvidovre
Responsible party
Lise Gluud (Associate Professor, Copenhagen University Hospital, Hvidovre) — Principal investigator
First posted
Feb 25, 2019
Start date
Feb 14, 2019
Primary completion
Jan 1, 2040 (estimated)
Completion
Jan 1, 2041 (estimated)
Last update
Apr 8, 2020

Study contacts

Srdan Novovic, PhD
Contact
srdan.novovic@regionh.dk
38623862
Lise L Gluud, MSc
Contact
lise.lotte.gluud.01@regionh.dk
+45 38621964

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion